Researchers at the National Center for Tumor Diseases (NCT) Heidelberg and the German Cancer Research Center (DKFZ) have developed a digital tool that significantly accelerates and improves clinical decisions in molecular precision oncology. The Knowledge Connector enables the structured and standardized evaluation of very extensive molecular tumor profiles and makes them available for personalized therapy decisions faster than before.

Exciva GmbH, a biopharmaceutical company developing novel therapeutic compounds for the treatment of neuropsychiatric conditions, today announces the closing of a €51 million ($59m) Series B financing round. Gimv and EQT Life Sciences co-led the round. Additional participants included new investors Fountain Healthcare Partners, LifeArc Ventures, Carma Fund and Modi Ventures, as well as existing investors Andera Partners and LBBW.

In a joint study conducted by the DZHK sites in Heidelberg, Munich and Göttingen, researchers are deciphering how the spatial organisation of the genome in the heart determines genetic disease risks.

At a time of geopolitical tensions and growing supply shortages, surgical capability is becoming a critical factor for resilient health systems. Hellstern medical GmbH has been accepted into the NATO DIANA innovation program with its key technology, the Robotic Surgeon Assist noac — NATO’s accelerator for defense and dual-use technologies.

Inflammation has to work fast against pathogens—but it can't get out of control. Researchers at the German Cancer Research Center (DKFZ) have now deciphered in more detail how the organism masters this balancing act. Their work shows that cells use two different strategies to precisely control inflammatory genes and thus precisely regulate the inflammatory response.